2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Ovarian Neoplasms
6
Advanced Solid Tumours
5
Squamous Cell Carcinoma of Head and Neck
4
Small Cell Lung Carcinoma
4
Uterine Cervical Neoplasms
3
Neoplasms
3
Lung Neoplasms
3
Leukemia, Myeloid, Acute
3
Glioblastoma
3
Fallopian Tube Neoplasms
3
Uterine Neoplasms
2
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Solid Tumors
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Multiple Myeloma
2
Lymphoma
2
Hematologic Neoplasms
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Advanced Malignant Solid Neoplasm
2
Vaginal Neoplasms
1
Urinary Bladder Neoplasms
1
Triple-negative Metastatic Breast Cancer
1
Tongue Neoplasms
1
Thyroid Neoplasms
1
Rhabdomyosarcoma
1
Interventions
tislelizumab
2
Cystectomy
2
vistusertib
1
toripalimab
1
olaparib
1
liposomal doxorubicin
1
durvalumab
1
disitamab vedotin
1
danvatirsen
1
adavosertib
1
Surgical Procedures, Operative
1
Rutin
1
Radiation
1
RC48 antibody
1
Neoadjuvant Therapy
1
Gemcitabine
1
Cisplatin
1
Chemoradiotherapy
1
AZD4547
1
AZD 6244
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Muscle Invasive Bladder Cancer
×
adavosertib
×
Clear all
NCT02546661
2025-12-29
BISCAY
AstraZeneca
Phase 1
Active not recruiting
117 enrolled